Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis

By Bacher Ulrike   Asenova Svetlana   Badbaran Anita   Zander Axel   Alchalby Haefaa   Fehse Boris   Kröger Nicolaus   Lange Claudia   Ayuk Francis  

Clinical and Experimental Medicine, Vol. 10, Iss. 3, 2010-09 ,pp. : 205-208

Springer Publishing Company

Access to resources Recommend Favorite

How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 481-491

John Wiley & Sons Inc

Access to resources Recommend Favorite

How we prevent and manage infection in sickle cell disease

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 6, 2015-09 ,pp. : 757-767

John Wiley & Sons Inc

Access to resources Recommend Favorite

How we manage clinical trials in the cellular therapy laboratory

By  

TRANSFUSION, Vol. 58, Iss. 1, 2018-01 ,pp. : 8-15

John Wiley & Sons Inc

Access to resources Recommend Favorite

Are we improving the outcome for patients with T‐cell prolymphocytic leukemia by allogeneic stem cell transplantation?

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 3, 2015-03 ,pp. : 191-192

John Wiley & Sons Inc

Access to resources Recommend Favorite